A Study of Thymoglobuline® Induction Therapy in Adult Recipients of Donated After Cardiac Death Kidney Transplant
Status:
Completed
Trial end date:
2019-11-12
Target enrollment:
Participant gender:
Summary
Primary Objective:
To investigate the efficacy of the standard dose of Thymoglobuline® induction therapy for
preventing acute rejection (AR) after transplantation among recipients of Donated after
Cardiac Death (DCD) kidney transplant.
Secondary Objectives:
- To evaluate delayed graft function (DGF), graft and patient survival after kidney
transplant.
- To evaluate adverse events of Thymoglobuline® throughout the study.
- To explore possible risk factors of AR and DGF in patients with DCD kidney transplant.
- To evaluate AR and DGF under different risk stratifications and explore an description
optimal induction therapy regimen for recipients of DCD kidney transplant.